| Multiple Myeloma |
1 |
1 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.95 |
| Lymphoma |
0 |
0.99 |
| Follicular Lymphoma |
0 |
0.77 |
| Biologic Therapy |
0 |
0.62 |
| B-Cell Lymphoma |
0 |
0.6 |
| HIV Infection |
0 |
0.49 |
| CAR-T |
0 |
0.27 |
| T-Lymphocyte |
0 |
0.22 |
| Stem Cell Research and Therapy |
0 |
0.21 |
| Chronic Lymphocytic Leukemia |
0 |
0.2 |
| Clinical Research |
0 |
0.19 |
| Immunomodulator |
0 |
0.19 |
| Refractory |
0 |
0.19 |
| Antineoplastic Drug |
0 |
0.13 |
| Tyrosine Kinase Inhibitor |
0 |
0.11 |
| Antigens |
0 |
0.1 |
| Cell Transplantation |
0 |
0.1 |
| Chemotherapy |
0 |
0.1 |
| Fatigue |
0 |
0.1 |
| Monoclonal Antibody |
0 |
0.1 |
| Transplantation |
0 |
0.1 |
| Tyrosine Kinase |
0 |
0.1 |
| Proteasome Inhibitor |
0 |
0.08 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.05 |
| Arizona |
0 |
0.05 |
| California |
0 |
0.05 |
| Cancer |
0 |
0.05 |
| Colorado |
0 |
0.05 |
| Corticosteroids |
0 |
0.05 |
| Food and Drug Administration (FDA) |
0 |
0.05 |
| Intravenous |
0 |
0.05 |
| Leukemia |
0 |
0.05 |
| Lymphocytes |
0 |
0.05 |
| Maryland |
0 |
0.05 |
| Nevada |
0 |
0.05 |
| New Jersey |
0 |
0.05 |
| New York |
0 |
0.05 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.05 |
| Oregon |
0 |
0.05 |
| Plasma |
0 |
0.05 |
| Quality of Life |
0 |
0.05 |
| Radiation Therapy |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Remission |
0 |
0.05 |
| Steroids |
0 |
0.05 |
| Texas |
0 |
0.05 |
| Virginia |
0 |
0.05 |